Key Highlights

  • CORT shares rose approximately 22% in pre-market trading to $113.35, up from a prior close of $92.95.
  • Second-quarter revenue reached $256.1 million, up 32% year over year and well above the roughly $221 million analyst estimate.
  • Adjusted earnings per share of $0.36 far exceeded the consensus estimate of a $0.04 loss.
  • The company raised full-year 2026 revenue guidance to a range of $1.1 billion to $1.2 billion.

Second-Quarter Results Sharply Exceed Estimates

Corcept Therapeutics Incorporated (NASDAQ:CORT) shares surged in pre-market trading after the company reported second-quarter results that significantly topped Wall Street expectations across both revenue and earnings. Corcept is a Redwood City, California-based commercial-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of the hormone cortisol to treat severe metabolic, oncologic, and neuropsychiatric disorders.

Revenue of $256.1 million was driven by authorized generic Korlym sales of $208.6 million alongside $47.6 million from Ralixar, the company's newer lithium-based oncology product, in its first full quarter of availability. Net income reached $43 million, up from $35 million in the prior-year period, while cash and investments stood at $545 million as of quarter end. The results build on strong momentum in the company's oncology launch, with more than 1,300 patients initiated on Ralixar for platinum-resistant ovarian cancer since its March 25 FDA approval.

Guidance Raise and Pipeline Catalysts Ahead

Following the results, Corcept raised its full-year 2026 revenue guidance to a range of $1.1 billion to $1.2 billion, up from a prior range of $950 million to $1.05 billion. Management indicated the Cushing's syndrome business alone is expected to reach at least $2 billion in annual revenue by the end of the decade, growing to $3 billion to $5 billion in 2026 with the addition of relacorilant, the company's planned successor to Korlym. The FDA has accepted relacorilant's New Drug Application resubmission for Cushing's syndrome, with a target action date of December 17.

Corcept carries a market capitalization of approximately $9.98 billion following the pre-market move, with shares trading within a 52-week range of $28.66 to $97.63. The stock had fallen sharply in regular trading in the days leading up to the report amid a bearish note from another research firm that had set an Underperform rating and $50 price target, citing valuation concerns ahead of pending regulatory catalysts.

Conclusion

Today's sharp gain reflects a decisive reversal of recent bearish sentiment following results that beat both revenue and earnings estimates by wide margins, alongside a substantial increase to full-year guidance. Investors will likely watch the December 17 FDA decision on relacorilant for Cushing's syndrome as the next major catalyst for the stock.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.